Wolska-Goszka L, Petlak A, Słomiński J M
Katedra i Klinika Chorób Płuc i Gruźlicy Akademii Medycznej w Gdańsku.
Pol Merkur Lekarski. 1999 Sep;7(39):99-101.
Recent studies indicate clinical value of intra-venous to oral switch therapy. The aim of this study was to analyze our results i.v. Cefotaxime to oral Cefetamet Piroxil switch therapy in lower respiratory tract infections. Group consists 35 patients in whom 27 has bacterial pathogen definitely established. Cefotaxim (Tarcefoksym-Polfa) i.v. has been used for 3-4 days followed with oral Cefetamet Pivoxil (Tarcevis-Polfa). Patients has been treated for 7 days in hospital and then as an out-patients afterwards. Excelent result has been observed in 27 cases (77% of the study group). Mild symptoms of medication intolerance has been observed in 8 patients (23% of all patients). Results of our experience with third generation cefalosporin i.v. to oral switch therapy are satisfactory. This method reduced total cost of treatment, reduced in-hospital days and was very well accepted by patients.
近期研究表明静脉转口服序贯疗法具有临床价值。本研究的目的是分析我们在治疗下呼吸道感染时，静脉使用头孢噻肟后转为口服头孢他美酯的治疗结果。该组包括35例患者，其中27例已明确确定有细菌病原体。静脉注射头孢噻肟（Tarcefoksym - Polfa）3 - 4天，随后口服头孢他美酯（Tarcevis - Polfa）。患者在医院接受7天治疗，之后作为门诊患者继续治疗。27例（占研究组的77%）观察到极佳效果。8例患者（占所有患者的23%）观察到轻微的药物不耐受症状。我们使用第三代头孢菌素静脉转口服序贯疗法的经验结果令人满意。这种方法降低了治疗总成本，减少了住院天数，并且患者接受度很高。
